Literature DB >> 34478132

Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.

Adriana-Michelle Wolf Pérez1, Nikolai Lorenzen2, Michele Vendruscolo3, Pietro Sormanni1.   

Abstract

Although antibodies have become the fastest-growing class of therapeutics on the market, it is still challenging to develop them for therapeutic applications, which often require these molecules to withstand stresses that are not present in vivo. We define developability as the likelihood of an antibody candidate with suitable functionality to be developed into a manufacturable, stable, safe, and effective drug that can be formulated to high concentrations while retaining a long shelf life. The implementation of reliable developability assessments from the early stages of antibody discovery enables flagging and deselection of potentially problematic candidates, while focussing available resources on the development of the most promising ones. Currently, however, thorough developability assessment requires multiple in vitro assays, which makes it labor intensive and time consuming to implement at early stages. Furthermore, accurate in vitro analysis at the early stage is compromised by the high number of potential candidates that are often prepared at low quantities and purity. Recent improvements in the performance of computational predictors of developability potential are beginning to change this scenario. Many computational methods only require the knowledge of the amino acid sequences and can be used to identify possible developability issues or to rank available candidates according to a range of biophysical properties. Here, we describe how the implementation of in silico tools into antibody discovery pipelines is increasingly offering time- and cost-effective alternatives to in vitro experimental screening, thus streamlining the drug development process. We discuss in particular the biophysical and biochemical properties that underpin developability potential and their trade-offs, review various in vitro assays to measure such properties or parameters that are predictive of developability, and give an overview of the growing number of in silico tools available to predict properties important for antibody development, including the CamSol method developed in our laboratory.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CamSol method; Developability; Immunogenicity; In silico; Prediction; Stability; Therapeutic antibody

Mesh:

Substances:

Year:  2022        PMID: 34478132     DOI: 10.1007/978-1-0716-1450-1_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  259 in total

1.  In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability.

Authors:  Vikas K Sharma; Thomas W Patapoff; Bruce Kabakoff; Satyan Pai; Eric Hilario; Boyan Zhang; Charlene Li; Oleg Borisov; Robert F Kelley; Ilya Chorny; Joe Z Zhou; Ken A Dill; Trevor E Swartz
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

Review 2.  Developability assessment during the selection of novel therapeutic antibodies.

Authors:  Alexander Jarasch; Hans Koll; Joerg T Regula; Martin Bader; Apollon Papadimitriou; Hubert Kettenberger
Journal:  J Pharm Sci       Date:  2015-03-26       Impact factor: 3.534

3.  Biophysical properties of the clinical-stage antibody landscape.

Authors:  Tushar Jain; Tingwan Sun; Stéphanie Durand; Amy Hall; Nga Rewa Houston; Juergen H Nett; Beth Sharkey; Beata Bobrowicz; Isabelle Caffry; Yao Yu; Yuan Cao; Heather Lynaugh; Michael Brown; Hemanta Baruah; Laura T Gray; Eric M Krauland; Yingda Xu; Maximiliano Vásquez; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

Review 4.  Third generation antibody discovery methods: in silico rational design.

Authors:  Pietro Sormanni; Francesco A Aprile; Michele Vendruscolo
Journal:  Chem Soc Rev       Date:  2018-12-10       Impact factor: 54.564

Review 5.  Understanding and predicting protein misfolding and aggregation: Insights from proteomics.

Authors:  Irantzu Pallarès; Salvador Ventura
Journal:  Proteomics       Date:  2016-09-12       Impact factor: 3.984

6.  Pricing of monoclonal antibody therapies: higher if used for cancer?

Authors:  Inmaculada Hernandez; Samuel W Bott; Anish S Patel; Collin G Wolf; Alexa R Hospodar; Shivani Sampathkumar; William H Shrank
Journal:  Am J Manag Care       Date:  2018-02       Impact factor: 2.229

7.  Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization.

Authors:  Tomoyuki Igawa; Shinya Ishii; Tatsuhiko Tachibana; Atsuhiko Maeda; Yoshinobu Higuchi; Shin Shimaoka; Chifumi Moriyama; Tomoyuki Watanabe; Ryoko Takubo; Yoshiaki Doi; Tetsuya Wakabayashi; Akira Hayasaka; Shoujiro Kadono; Takuya Miyazaki; Kenta Haraya; Yasuo Sekimori; Tetsuo Kojima; Yoshiaki Nabuchi; Yoshinori Aso; Yoshiki Kawabe; Kunihiro Hattori
Journal:  Nat Biotechnol       Date:  2010-10-17       Impact factor: 54.908

8.  Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility.

Authors:  Lilia A Rabia; Alec A Desai; Harkamal S Jhajj; Peter M Tessier
Journal:  Biochem Eng J       Date:  2018-06-05       Impact factor: 3.978

9.  Five computational developability guidelines for therapeutic antibody profiling.

Authors:  Matthew I J Raybould; Claire Marks; Konrad Krawczyk; Bruck Taddese; Jaroslaw Nowak; Alan P Lewis; Alexander Bujotzek; Jiye Shi; Charlotte M Deane
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-14       Impact factor: 11.205

Review 10.  Antibodies to watch in 2020.

Authors:  Hélène Kaplon; Mrinalini Muralidharan; Zita Schneider; Janice M Reichert
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

View more
  2 in total

1.  Functional and structural analysis of non-synonymous single nucleotide polymorphisms (nsSNPs) in the MYB oncoproteins associated with human cancer.

Authors:  Shu Wen Lim; Kennet JunKai Tan; Osman Mohd Azuraidi; Maran Sathiya; Ee Chen Lim; Kok Song Lai; Wai-Sum Yap; Nik Abd Rahman Nik Mohd Afizan
Journal:  Sci Rep       Date:  2021-12-17       Impact factor: 4.379

2.  Antibody apparent solubility prediction from sequence by transfer learning.

Authors:  Jiangyan Feng; Min Jiang; James Shih; Qing Chai
Journal:  iScience       Date:  2022-09-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.